Cytomegalovirus Retinitis Market Assesses the Future Impact of the Propellants, Potential Demands and Restraints on the Market

One of the major trends noticed in the cytomegalovirus retinitis market is usage of off-label drugs for the treatment of cytomegalovirus retinitis.

Sponsored Link Spot Available — Get This Spot Innovation of products focusing on better efficacy, growing demographics and growing economies in the developing countries, such as China and India, are some of the opportunities for global cytomegalovirus retinitis market.

Cytomegalovirus retinitis is eye disease caused due to retina inflammation of eye. The causative agent of the disease is cytomegalovirus, a herpes virus that affects the photosensitive cells of retina. After affecting the retina, the disease spreads from one eye to another eye, which can lead to blindness, if left untreated. Photophobia, blurred vision, seeing floaters and blind spots are the symptoms of cytomegalovirus retinitis. Cytomegalovirus retinitis usually affects people with weak immune system, including HIV affected patients. Various forms of cytomegalovirus retinitis medication are solutions, capsules, tablets and implants.

Access Detailed Report Summary:
https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market

Cytomegalovirus retinitis is an emergency situation because if a black spot in the visual field appears once, the disease cannot be cured due to its permanent in nature. If posterior pole is involved, it leads to approximately one half of incident visual acuity loss. Ophthalmology is the branch of medical science that deals with the study and management of physiology, anatomy and the diseases related to the human eye. The vision loss and incidence of eye disorders are becoming a major public health issues which include various eye diseases such as glaucoma, age-related macular degeneration, cataract, diabetic macular edema, retinal detachment, ocular hypertension, bulging eyes, refractive errors and uveitis. Active cytomegalovirus retinitis is generally treated by uveitis or ocular immunology specialist. Fomivirsen was the first antisense drug approved by the U.S. Food and Drug Administration (FDA) as an intraocular injection for curing cytomegalovirus retinitis. As the virus creates a worse effect to vision, it is generally treated by a vitreoretinal surgeon with the help of antivirals, such as ganciclovir or foscarnet, which can be taken orally or directly into the eye.

Request to Get the Sample Pages at:
https://www.psmarketresearch.com/market-analysis/cytomegalovirus-retinitis-market/report-sample

Increasing incidence of cytomegalovirus retinitis cases, rising government initiatives towards healthcare infrastructure and enhancement of healthcare facilities are some of the major factors driving the global cytomegalovirus retinitis market growth.

Some of the major factors restraining the growth of the global cytomegalovirus retinitis market are lack of awareness among people for different types of eye diseases, rising healthcare cost in developing countries and lack of healthcare insurance. Majority of the population do not have proper access to primary healthcare services because of poverty and absence of health insurance, which is also hindering the growth of cytomegalovirus retinitis market. The other major challenge for the global cytomegalovirus retinitis market is lack of approved treatment guidelines by the World Health Organization (WHO).

Some of the major competitors of global cytomegalovirus retinitis market are, Shire Plc, F. Hoffmann-La Roche AG, Hospira Inc., Chimerix Inc., Gilead Sciences Inc., pSivida, Auritec Pharmaceuticals Inc., Sanofi S.A., and Isis Pharmaceuticals Inc.
Contact Email
[email protected]
Issued By
Pramod Kumar
Phone
03479606455
Business Address
Block-13, Sector 2, Noida, Uttar Pradesh - 201301 India
Country
India
Categories
Medical · Reports · Research
Last Updated
December 6, 2019

Disclaimer: This press release was submitted by a registered PRBASE contributor and has not been verified or endorsed by PRBASE. PRBASE assumes no responsibility or liability for its accuracy, content, legality, or reliability. The contact email for this release can be viewed here. See our Disclaimer.

Delete Press Release · Edit Press Release